MGT-1141 / Marigold Therapeutics - LARVOL DELTA

MGT-1141, an antibody-drug-conjugate targeting DLL3 positive cancers (AACR 2026) - "Preclinical evaluations of MGT-1141 have shown potent and selective anti-tumor activity, favorable pharmacokinetic properties, and a well-tolerated safety profile, supporting its further development toward clinical investigation. Collectively, these findings support MGT-1141 as a promising and potential best-in-class DLL3-targeting ADC for the treatment of SCLC and NECs."

ADC • Endocrine Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3